Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824349) titled 'JUR-003 in Adult Patients With Metastatic Prostate Cancer' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Juri Biosciences, Inc.
Condition:
Metastatic Castration Resistant Prostate Cancer
Oligometastatic Prostate Cancer (OMPC)
Metastatic Hormone Sensitive Prostate Cancer
Intervention:
Biological: JUR-003
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 210
Countries of Recruitment:
United Sta...